The medical community is deeply divided over the FDA advisory panel’s July 2026 decision to ease compounding restrictions on popular wellness peptides like BPC-157, TB-500, KPV, and MOTS-c. While some industry-aligned doctors praise the move for restoring autonomy to the patient-physician relationship, independent medical experts and FDA staff scientists strongly warn that the hype is severely outpacing the science, creating major risks for consumers.
Become a supporter of this podcast: https://www.spreaker.com/podcast/today-explained--6659607/support.
Don’t miss our latest episodes! follow us to stay updates with fresh news everyday. Let’s keep the support our podcast to serve update news entire the world!